Command Palette

Search for a command to run...

JUBLPHARMA

1104-1.80%
Market Cap
₹17,837.10 Cr
Stock P/E
38.76
ROCE
13.92%
ROE
14.35%
Book Value
₹398.22

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Growth Outperformer

Jubilant Pharmova Ltd. shows moderate revenue growth and decent profitability metrics compared to its peers in the pharmaceuticals sector, though it has the highest PE ratio, indicating potential overvaluation. Companies like Cipla and Dr. Reddy's stand out for their profitability and growth, while others like Divi's Laboratories face challenges with growth despite high profitability metrics. Overall, Jubilant Pharmova is positioned as a moderate growth player in a competitive landscape.

Key Points
  • Jubilant Pharmova has moderate revenue growth (6.7% YoY) but high PE ratio (494.25).
  • Cipla and Dr. Reddy's lead in profitability measures with strong ROE and margins.
  • Divi's Laboratories, despite high EBITDA margins, has poor revenue growth and EPS trajectory.
  • Sun Pharma and Divi's show strong profitability but also higher valuations.
Top Performers
Cipla Ltd.

Leads in profitability metrics with a PE of 23.73 and strong revenue growth at 13.28% YoY.

Dr. Reddy's Laboratories Ltd.

High ROE (21.76%) and strong EPS growth (68.07) make it a top performer.

Mankind Pharma Ltd.

Significant revenue growth (18.12% YoY) and solid profitability metrics.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.